MYRIAD GENETICS DL-,01 | 17.795 / -0.34% |
Date/Time | 06/24 / 21:43 |
Chg. / Chg.(%) | -0.060 / -0.34% |
Bid | 17.905 / 279 |
Ask | 17.970 / 279 |
Open | 17.950 |
Previous Close | 17.855 |
High | 18.170 |
Low | 17.795 |
Volume [EUR] | - |
Volume [Units] | |
Price fixings | 9 |
ISIN | US62855J1043 |
Security | MYD |
Exchange | gettex |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 17.755 | ![]() |
|
NASDAQ | 18.9500 | ![]() |
814,931 |
IEX | 18.95 | ![]() |
49,774 |
Cboe US | 18.92 | ![]() |
13,898 |
London Domes.. | 19.45 | ![]() |
31 |
Hannover | 17.955 | ![]() |
0 |
Frankfurt | 17.9650 | ![]() |
0 |
Berlin | 17.945 | ![]() |
0 |
München | 17.945 | ![]() |
0 |
Hamburg | 17.955 | ![]() |
0 |
Düsseldorf | 17.830 | ![]() |
0 |
Stuttgart | 17.950 | ![]() |
0 |
gettex | 17.795 | ![]() |
|
Quotrix | 18.0500 | ![]() |
|
TradeGate | 16.450 | 600 | |
Xetra | 16.450 | 0 |
News
- Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
03/14/2022 / 12:05 - GlobeNewswire - Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
03/12/2022 / 01:05 - GlobeNewswire - Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
03/08/2022 / 13:22 - GlobeNewswire - Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference
03/02/2022 / 22:30 - GlobeNewswire - Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
02/24/2022 / 15:00 - GlobeNewswire
Personal area
Click on
to activate push quotes.
